MEKICS has established core integrated technologies and accumulated extensive experience
in managing patients with a wide spectrum of respiratory conditions—from mild to severe. Furthermore, in line with the “new demands” and “new globalization” brought about
by the COVID-19 pandemic, MEK is still introducing new respiratory solutions to the market.
in managing patients with a wide spectrum of respiratory conditions—from mild to severe. Furthermore, in line with the “new demands” and “new globalization” brought about
by the COVID-19 pandemic, MEK is still introducing new respiratory solutions to the market.
Opening a New Path in Respiratory Care Solutions
- Laying the foundation through the development of patient monitoring systems.
-
1998.
- Korea’s First Hand-held Pulse Oximeter Developed
-
2000.
- Korea’s First Hand-held Pulse Oximeter Developed
Establishment of Mec Co., Ltd.
Korea’s First Five-Parameter Patient Monitor Featuring a Digital Scan Converter
- Korea’s First Hand-held Pulse Oximeter Developed
Expansion into Critical Care: Leading the Advancement of Technology
- Korea’s first successful development of a mechanical ventilator
- Development of next-generation respiratory therapy systems
-
2008.
- Establishing a strong and reliable position in the mid-range ventilator market
MV2000 series : MEKANT – SU:M – EVO2 – EVO5
MV2000 Critical-Care Ventilator System developed
- Establishing a strong and reliable position in the mid-range ventilator market
Advancing Unique Korean Technology Toward Global Standards
- Focused investment in world-leading product lines built on proprietary technologies
- Designed to support diverse care environments—from hospitals to home settings
-
2015.
- Listed in KOSDAQ
-
2016.
- Establishment of Yantai Sejong Co., Ltd. in China
Establishment of the subsidiary MEK Healthcare
- Establishment of Yantai Sejong Co., Ltd. in China
Driving Innovation Through Comprehensive Respiratory Care Solutions
- Introducing a new paradigm in respiratory therapy with the development of OmniOx
- Establishing a new standard for High-Flow Nasal Cannula (HFNC) therapy
-
2018.
- Launch of the total respiratory care service “My-SUMM”
Development of the next-generation HFNC device OmniOx 700
- Launch of the total respiratory care service “My-SUMM”
-
2022.
- Development of the HFNC + NIV device OmniOx 750
-
2024.
- Development of the HFNC + NIV + IV device OmniOx 750
Expanding Our Reach into Global Respiratory Care
- Introducing advanced solutions for patient data management and monitoring
- Establishing global localization initiatives and strategic manufacturing partnerships
-
2025.
- Patient Data Management System, Meerkat Platform developed
OmniOx Japan PMDA Approved
OmniOx FDA Approved
- Patient Data Management System, Meerkat Platform developed